"It is integrated into everything that we do," says Merck's chief information and digital officer Dave Williams.

We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates ...

Zacks Research lowered their Q3 2024 earnings estimates for Merck & Co., Inc. in a report issued on Monday, October 21st.

Merck KGaA cut its mid-term sales growth target for its health-care division after a number of high-profile drug trial ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing ...

Merck KGaA lowered its medium-term outlook for its healthcare and life-science segment due to China challenges and recent ...

German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May ...

TIME convened the first-ever TIME100 Health Leadership Forum to bring together individuals driving innovation and creating equitable initiatives within the health sector.

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...